Dr. Su Joins UCLA as an Assistant Professor in Chemical and Biomolecular Engineering
We’re thrilled to share that Dr. Ida Su has joined the University of California, Los Angeles as an Assistant Professor in the Department of Chemical and Biomolecular Engineering within the UCLA Samueli School of Engineering.
In this role, Ida brings her expertise in immunoengineering, RNA delivery, and engineered cell therapy to one of the nation’s leading engineering research communities. The Su lab will embark on research that bridges chemical engineering principles with cutting-edge nanomaterials and immunotherapy innovation.
UCLA’s Chemical and Biomolecular Engineering department is internationally recognized for its multidisciplinary research and educational excellence, uniting chemistry, biology, physics, and engineering to tackle some of the most pressing scientific and societal challenges. Faculty and students work across diverse areas—from biomolecular engineering and nanoengineering to process systems design and energy and environmental solutions—and the department maintains strong ties with medical, biotechnology, and clinical partners on campus and beyond. This collaborative ecosystem creates an ideal environment for Ida’s work on immunoengineering that interacts with biological systems to modulate immune responses.
UCLA campus
The Su Lab at UCLA will build on Ida’s expertise in mRNA delivery, cell engineering, and cell-based therapies to enhance immune system function for disease treatment.
Her research will contribute to a broader effort within the department to integrate biomolecular design with translational applications in health care and medicine. With her appointment, Ida is looking forward to working with students and collaborators at UCLA to push the boundaries of what’s possible in engineered immunotherapies and targeted molecular interventions.
About the Su Lab
The Su Lab at UCLA is advancing the frontiers of cell engineering to develop transformative immunotherapies for cancer, autoimmune diseases, and beyond. We bring together biomolecular engineering, nanotechnology, immunology, and cell engineering to build platform technologies that reshape how immune therapies work. By focusing on antigen specificity, precision immune modulation, and disease-tailored cellular responses, we aim to overcome the major barriers that limit current treatments—such as non-specific immune activation, severe side effects, and poor outcomes against solid tumors.
